Your browser doesn't support javascript.
loading
New Therapeutic Approaches to Inherited Metabolic Pediatric Epilepsies.
Pearl, Phillip L; Tokatly Latzer, Itay; Lee, Henry H C; Rotenberg, Alexander.
Afiliação
  • Pearl PL; From the Department of Neurology (P.L.P., I.T.L., H.H.C.L., A.R.), Boston Children's Hospital, Harvard Medical School, Boston, MA. phillip.pearl@childrens.harvard.edu.
  • Tokatly Latzer I; From the Department of Neurology (P.L.P., I.T.L., H.H.C.L., A.R.), Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Lee HHC; From the Department of Neurology (P.L.P., I.T.L., H.H.C.L., A.R.), Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Rotenberg A; From the Department of Neurology (P.L.P., I.T.L., H.H.C.L., A.R.), Boston Children's Hospital, Harvard Medical School, Boston, MA.
Neurology ; 101(3): 124-133, 2023 07 18.
Article em En | MEDLINE | ID: mdl-36878704
Treatment options for inherited metabolic epilepsies are rapidly expanding with advances in molecular biology and the genomic revolution. Traditional dietary and nutrient modification and inhibitors or enhancers of protein and enzyme function, the mainstays of therapy, are undergoing continuous revisions to increase biological activity and reduce toxicity. Enzyme replacement and gene replacement and editing hold promise for genetically targeted treatment and cures. Molecular, imaging, and neurophysiologic biomarkers are emerging as key indicators of disease pathophysiology, severity, and response to therapy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epilepsia Limite: Child / Humans Idioma: En Revista: Neurology Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epilepsia Limite: Child / Humans Idioma: En Revista: Neurology Ano de publicação: 2023 Tipo de documento: Article